Comparative Pharmacology
Head-to-head clinical analysis: LORCET HD versus TYLOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LORCET HD versus TYLOX.
LORCET-HD vs TYLOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a mu-opioid receptor agonist, modulating pain perception and emotional response to pain. Acetaminophen inhibits cyclooxygenase (COX) and modulates descending serotonergic pathways, providing antipyretic and analgesic effects.
Tylox combines oxycodone, a mu-opioid receptor agonist, with acetaminophen, which inhibits cyclooxygenase (COX) and modulates descending serotonergic pathways.
1-2 tablets (hydrocodone 5-10 mg / acetaminophen 325-650 mg) orally every 4-6 hours as needed for pain; maximum acetaminophen 4 g/day (or 3 g/day in at-risk patients).
1-2 capsules (oxycodone 5 mg/acetaminophen 325 mg) orally every 6 hours as needed for pain; maximum 12 capsules per day.
None Documented
None Documented
Morphine: 2-4 hours; hydrocodone: 3.8-6 hours. Clinical context: Immediate-release, dosing every 4-6 hours.
Oxycodone: 3.5-5.6 hours; acetaminophen: 2-3 hours. In hepatic impairment, oxycodone half-life prolonged up to 13 hours.
Renal: 90% as morphine-3-glucuronide and morphine-6-glucuronide, 10% as unchanged morphine; biliary: minor (<5%); fecal: <5%.
Renal: oxycodone ~19% unchanged; acetaminophen ~2-5% unchanged. Biliary: minimal. Fecal: <5% total. Total renal elimination: ~60-70% as metabolites of oxycodone (noroxycodone, oxymorphone) and acetaminophen conjugates.
Category C
Category C
Opioid analgesic combination
Opioid analgesic combination